Growth in HIV-1-exposed but uninfected infants treated with lopinavir–ritonavir versus lamivudine: a secondary analysis of the ANRS 12174 trial

Publication date: Available online 24 February 2019Source: The Lancet HIVAuthor(s): Stéphane Blanche, Thorkild Tylleskär, Marianne Peries, Chipepo Kankasa, Ingunn Engebretsen, Nicolas Meda, James K Tumwine, Mandisa Singata-Madliki, Mwiya Mwiya, Philippe Van de Perre, Nicolas Nagot, ANRS 12174 Trial GroupSummaryBackgroundThe tolerance of antiretroviral drugs in infants must be carefully evaluated. In previous studies of children with HIV type 1 (HIV-1) less weight gain was observed in children given lopinavir–ritonavir-based combinations than those given nevirapine. We aimed to compare the effects of lopinavir–ritonavir and lamivudine on growth in HIV-exposed uninfected infants included in the ANRS 12174 trial.MethodsANRS 12174 was a multicentre, randomised, controlled trial of infant prophylaxis to prevent HIV-1 transmission by breastfeeding done at four antenatal clinics in Burkina Faso, South Africa, Uganda, and Zambia. HIV-exposed uninfected infants born to asymptomatic mothers not eligible for antiretroviral therapy (CD4 count>350 cells per μL) were randomly assigned (1:1) to receive lopinavir–ritonavir or lamivudine 7 days after birth, with stratification by country. In a prespecified secondary analysis, we assessed the effect of lopinavir–ritonavir and lamivudine on the growth of these infants from day 7 until cessation of breastfeeding (maximum treatment time 12 months) in the modified intention-to-treat population, which included all children correctly enro...
Source: The Lancet HIV - Category: Infectious Diseases Source Type: research